[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641907":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":33,"locations":43,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":25,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Masaryk Memorial Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventional","EXPERIMENTAL","Participants with locally advanced potentially resectable esophageal, gastric, or pancreatic cancer receiving neoadjuvant\u002Fperioperative treatment will undergo serial blood sampling for plasma isolation and circulating tumor DNA (ctDNA) analysis. Samples will be collected prior to initiation of neoadjuvant therapy, at the time of surgery, and subsequently at approximately 3-month intervals for 1-2 years after surgery or until disease progression. ctDNA analyses will be performed using a targeted next-generation sequencing (NGS) approach to evaluate longitudinal changes in tumor-specific genomic alterations and their association with treatment response and disease recurrence.",[13],"Diagnostic Test: NGS sequencing of mutations selected based on sequencing of primary tumors",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","ACTIVE_COMPARATOR","Participants with esophageal, gastric, or pancreatic cancer receiving first-line palliative systemic therapy will undergo serial blood sampling for plasma isolation and ctDNA analysis. Samples will be collected prior to initiation of systemic treatment and subsequently at approximately 3-month intervals during first-line therapy. ctDNA analyses will be performed using the same targeted NGS methodology to assess longitudinal changes in tumor-specific genomic alterations during systemic treatment.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","NGS sequencing of mutations selected based on sequencing of primary tumors","Sequencing of the primary tumor will be performed on a MiSeq instrument using the Accel-Amplicon panel, which covers the most common mutations. For deep sequencing of ctDNA, 2-3 genomic regions carrying mutations in the primary tumor will be selected for the patient. For these regions, sets of universal primers will be designed to amplify the mutations most commonly found in solid tumors (RAS, BRAF, TP53, EGFR, APC, etc.). Another set of universal primers will contain a sequence for indexing individual samples, enabling the parallel sequencing of up to 96 samples simultaneously. The sequencing library will be analyzed on a NextSeq 500 instrument, which allows for up to 400 million reads in a single sequencing run. The sequencing results will then be correlated with the clinical course of the disease.",[15,9],null,[27,30],{"name":28,"affiliation":5,"role":29},"Petr Müller, MD, PhD","STUDY_DIRECTOR",{"name":31,"affiliation":5,"role":32},"Radka Lordick Obermannová, MD, Doc, PhD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Martina Lojová, PhD","CONTACT","+420543136232","martina.lojova@mou.cz",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Tereza Štěpánková, PhD","+420543136223","tereza.stepankova@mou.cz",[44],{"facility":5,"status":45,"city":46,"state":25,"zip":47,"country":48,"countryCode":25,"cosmosGeoPoint":49,"geoPoint":54,"contacts":25},"RECRUITING","Brno","65653","Czechia",{"type":50,"coordinates":51},"Point",[52,53],16.60796,49.19522,{"lat":53,"lon":52},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100641907","determining-minimal-residual-disease-using-ctdna-deep-sequencing-100641907",false,"NCT07660627","Determining Minimal Residual Disease Using ctDNA Deep Sequencing","Determination of Minimal Residual Disease by Deep ctDNA Sequencing.","CIT-SEQ","Inclusion Criteria:\n\n* Consent to participate in the study\n* Patients with esophageal, gastric, or pancreatic cancer, stage 0-2\n* Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy\n* Patients with metastatic disease treated with first- to third-line palliative systemic therapy\n\nExclusion Criteria:\n\n* not specified","ALL",{"count":67,"type":68},34,"ESTIMATED","INTERVENTIONAL",[71],"NA","Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse\u002Fprogression of disease.",[74,75,76],"Esophageal Adenocarcinoma","Gastric Cancer","Pancreatic Cancer",[78,79,80,81],"Minimal residual disease","NGS sequencing","gastrointestinal tumors","Preoperative neoadjuvant chemotherapy","2026-06-19",{"date":84,"type":85},"2026-06-24","ACTUAL",{"date":87,"type":85},"2022-08-22",{"date":89,"type":68},"2026-12-31",{"name":5,"class":6},1]